Evotec SENASDAQ:EVO
- LAST PRICE10.4501
- TODAY'S CHANGE (%)0.0005 (0.0048%)
- Bid / Lots7.8000/ 1
- Ask / Lots10.8000/ 5
- Open / Previous Close10.5900 / 10.4496
- Day Range
- 52 Week Range
- Volume5,568
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | EVO |
|---|---|---|
| 09:41 ET | 100 | 10.59 |
| 09:52 ET | 200 | 10.63 |
| 09:54 ET | 688 | 10.64 |
| 09:57 ET | 100 | 10.63 |
| 03:50 ET | 1000 | 10.4501 |
Mar 28, 2023
Evotec's Preliminary 2022 Operating Income Declines, Revenue Rises, from 9:24AM ET on Tuesday Mar 28, 2023 by MT Newswires
9:24AM ET on Tuesday Mar 28, 2023 by MT NewswiresEvotec, Bristol-Myers Squibb Extend Partnership on Neurodegenerative Diseases for Eight Years, from 6:05AM ET on Tuesday Mar 28, 2023 by MT Newswires
6:05AM ET on Tuesday Mar 28, 2023 by MT NewswiresEvotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration Partnership, from 5:20AM ET on Tuesday Mar 28, 2023 by Accesswire
5:20AM ET on Tuesday Mar 28, 2023 by AccesswireEvotec SE Preliminary Fiscal Year 2022 Results: 'Ahead of the Curve' - Very Strong Performance in a Challenging Year, from 1:30AM ET on Tuesday Mar 28, 2023 by Accesswire
1:30AM ET on Tuesday Mar 28, 2023 by Accesswire
Mar 24, 2023
Evotec Gets $6.6 Million Grant From Gates Foundation, from 5:19AM ET on Friday Mar 24, 2023 by MT Newswires
5:19AM ET on Friday Mar 24, 2023 by MT Newswires
Industry Peers
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Evotec SE | --- | 0.0x | --- |
Company Information
Evotec SE is a Germany-based drug discovery and development company. The company is engaged in development of new pharmaceutical products through research alliances and development partnerships with pharmaceutical and biotechnology companies, academic institutions, patient organizations and venture capital companies. The drug discovery solutions are provided in the form of fee-for-service work, integrated drug discovery alliances, development partnerships, licensing of drug candidates and consulting arrangements. Evotec SE operates in a number of areas, including neuroscience, diabetes and complications of diabetes, pain and inflammation, oncology, infectious diseases, respiratory diseases and fibrosis. Its pipeline covers a range of therapeutic areas, such as CNS Insomnia, Chronic cough, immunology & inflammation, women’s health endometriosis, nephrology, dermatological diseases, fibrotic disease and antiviral, among others.
Contact Information
- Headquarters
- Essener Bogen 7HAMBURG, Germany 22419
- Phone
- ---
- Fax
- 405-608-1222
Executives
- Independent Chairman of the Supervisory Board
- Iris Loew- Friedrich
- Chief Executive Officer, Member of the Management Board
- Werner Lanthaler
- Independent Vice Chairman of the Supervisory Board
- Roland Sackers
- Chief Financial Officer, Member of the Management Board
- Enno Spillner
- Chief Operating Officer, Member of the Management Board
- Craig Johnstone
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | --- |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | --- |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | --- |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
